Abaloparatide Featured in ECTS Position Statement on Male Osteoporosis

A new publication referencing abaloparatide appeared on October 6, 2026. The paper, titled "Treatment of male osteoporosis: a narrative review and position statement by the ECTS Clinical Action Group," was published in the Journal of Bone and Mineral Research. This is the official journal of the American Society for Bone and Mineral Research. The publication is described as a narrative review combined with a position statement from the ECTS Clinical Action Group. No findings, conclusions, or recommendations from the paper have been provided beyond its title and journal of publication. Abaloparatide is noted as an approved compound in this context. Readers interested in the specifics of the review, including any positions taken on treatment approaches for male osteoporosis, are encouraged to consult the original source directly. For general background on abaloparatide, including its approved status and other available information, readers can refer to the compound overview.